AbbVie has entered into an exclusive worldwide license agreement with C2N Diagnostics to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders Read the full story
AbbVie has entered into an exclusive worldwide license agreement with C2N Diagnostics to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders Read the full story
AbbVie will acquire Pharmacyclics, and its flagship asset Imbruvica (ibrutinib), a highly effective treatment for hematologic malignancies Read the full story
AbbVie has acquired a small molecule active pharmaceutical ingredient (API) manufacturing site in Singapore's Tuas Biomedical Park Read the full story
ENTEROME Bioscience has entered into a collaborative development agreement with AbbVie Read the full story
In response to recent changes to the U.S. tax code to discourage so-called tax inversion deals, Chicago-based AbbVie recently indicated it was rethinking its $54 billion takeover bid of U.K.-based Shire. Read the full story
Shire has finally agreed for an m&a agreement with AbbVie for $54 billion. Read the full story
Abbvie, a top global biopharmaceutical company headquartered in the United States, focusses on solving threatening health problems. A recently formed company in 2013, Abbvie was formed as a separate research based pharma company from Abbott. Read the full story
The boss of US drug-maker AbbVie is flying into London this week to court Shire’s shareholders and try to convince them of the merits of a potential takeover. Read the full story
Abbvie has acquired only one company in 2010 with the purchase of Facet Biotechnology valued at $722 million. Read the full story
Shire rejects Abbvie's $46 billion bid for acquisition. Read the full story